High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma

被引：0
|
作者：
Quan, WDY
Taylor, WC
Ramirez, M
Vinogradov, M
Khan, N
Jackson, S
机构：
[1] Univ Texas, Med Branch, Galveston, TX 77550 USA
[2] E Carolina Univ, Sch Med, Greenville, NC USA
[3] Med Coll Ohio, Div Med Oncol & Hematol, Coll Med, Toledo, OH 43699 USA
来源：
JOURNAL OF IMMUNOTHERAPY | 2004年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S5 / S6
页数：2
相关论文
共 50 条
  • [31] A PHASE-II STUDY OF HIGH-DOSE CONTINUOUS INFUSION INTERLEUKIN-2 WITH LYMPHOKINE-ACTIVATED KILLER-CELLS IN PATIENTS WITH METASTATIC MELANOMA
    DUTCHER, JP
    GAYNOR, ER
    BOLDT, DH
    DOROSHOW, JH
    BAR, MH
    SZNOL, M
    MIER, J
    SPARANO, J
    FISHER, RI
    WEISS, G
    MARGOLIN, K
    ARONSON, FR
    HAWKINS, M
    ATKINS, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (04) : 641 - 648
  • [32] Correlation between development of pulmonary edema and response of pulmonary metastases of metastatic melanoma and kidney cancer to high-dose continuous-infusion interleukin-2
    Quan, WDY
    Khan, N
    Ramirez, M
    Taylor, WC
    Quan, F
    Vinogradov, M
    Walker, P
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2005, 20 (02) : 151 - 154
  • [33] COMPLEMENT ACTIVATION AND HIGH-DOSE OF INTERLEUKIN-2
    THIJS, LG
    HACK, CE
    VANSCHIJNDEL, RJMS
    NUIJENS, JH
    WOLBINK, GJ
    EERENBERGBELMER, AJM
    VANDERVALL, H
    WAGSTAFF, J
    [J]. LANCET, 1989, 2 (8659): : 395 - 395
  • [34] Managing toxicities of high-dose interleukin-2
    Schwartz, RN
    Stover, L
    Dutcher, J
    [J]. ONCOLOGY-NEW YORK, 2002, 16 (11): : 11 - 20
  • [35] CONTINUOUS INTRAVENOUS-INFUSION OF HIGH-DOSE RECOMBINANT INTERLEUKIN-2 FOR ADVANCED LYMPHOMAS - A PHASE-II STUDY
    LIM, SH
    WORMAN, CP
    CALLAGHAN, T
    JEWELL, A
    SMITH, MP
    GOLDSTONE, AH
    [J]. LEUKEMIA RESEARCH, 1991, 15 (06) : 435 - 440
  • [36] High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: The University of Chicago experience
    Shulman, KL
    Stadler, WM
    Vogelzang, NJ
    [J]. UROLOGY, 1996, 47 (02) : 194 - 197
  • [37] High-Dose Interleukin-2: Is It Still Indicated for Melanoma and RCC in an Era of Targeted Therapies?
    Amin, Asim
    White, Richard L., Jr.
    [J]. ONCOLOGY-NEW YORK, 2013, 27 (07): : 680 - 691
  • [38] INTERLEUKIN-2 AND HIGH-DOSE CISPLATIN IN PATIENTS WITH METASTATIC MELANOMA - A PILOT-STUDY
    DEMCHAK, PA
    MIER, JW
    ROBERT, NJ
    OBRIEN, K
    GOULD, JA
    ATKINS, MB
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (10) : 1821 - 1830
  • [39] The treatment of disseminated skin melanoma with high-dose recombinant interleukin-2 in combination with chemotherapy
    Streltsova, O.
    Baranau, Y.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [40] Should High-Dose Interleukin-2 Still Be the Preferred Treatment for Patients with Metastatic Melanoma?
    Dillman, Robert O.
    Barth, Neil M.
    VanderMolen, Louis A.
    Mahdavi, Khosrow
    McClure, Stephanie E.
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2012, 27 (06) : 337 - 343
12345